Create a Report

Please provide report title
Please provide location
Please provide details

Get alerts and updates for your case!

This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.

Please provide email or phone
Please provide email or phone

We do not show your email or contact info

Skip this step

Add photos or video

We recommend photos and videos to help explain your report

Add Photo/Video
Skip this step

Email or SMS copy of report

Enter below to get emailed a copy of your report, or sms a link to your report

Please provide email or phone
Please provide email or phone

Thank you for your report!

The report was
successfully sent!


Your report is queued - it may take up to 12 hours to process your report.


Email us at support@safelyhq.com if you have questions.

Report by

Safety Report: Sagent Docetaxel Injection, USP - recalled due to presence of particulate matter, USA

1 month ago source fda.gov

Recall notice

United States

Sagent Pharmaceuticals today announced the voluntary recall of two lots of Docetaxel Injection, USP to the User Level as the result of a customer complaint due to the potential presence of particulate matter from the stopper in the drug product. The product was distributed by Sagent Pharmaceuticals nationwide from October 11, 2023, to April 11, 2024. .

Intravenous administration of an injectable product that contains particulate matter may result in serious adverse events. Potential complications related to injection of particles include inflammation of a vein, granuloma, and blockage of blood vessels in the heart, lungs or brain which can cause stroke or life-threatening blood clot events. The frequency and severity of these adverse events could vary depending upon a variety of factors including the size and number of particles in the drug product, patient comorbidities (such as age, compromised organ function), and presence or absence of vascular anomalies.

The Docetaxel Injection, USP, label and affected lot numbers with Expiration Dates and NDC number can be found below:
- Product: DOCETAXEL INJECTION, USP, Lot Number: F1030001, NDC: 25021-254-16, Expiration Date: 12/2024, Strength: 160 mg/16 mL (10 mg/mL).
- Product: DOCETAXEL INJECTION, USP, Lot Number: F1040001, NDC: 25021-254-08, Expiration Date: 12/2024, Strength: 80 mg/8 mL (10 mg/mL).

Customers are being notified by a FedEx package that includes arrangements for return of all recalled product. Customers are instructed to examine their inventory immediately and to quarantine, discontinue distribution of and return the recalled lots listed above.

Customers who may have further distributed this product have been requested to identify their customers and notify them at once of this product recall. Consumers/distributors/retailers that have product which is being recalled should stop using product and return the recalled product.

In case you experienced harm from extraneous materials, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance. If symptoms persist, seek medical care.

Company name: Sagent Pharmaceuticals
Brand name: Sagent
Product recalled: Docetaxel Injection, USP
Reason of the recall: Potential presence of particulate matter
FDA Recall date: May 29, 2024

Source: www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sagent-pharmaceuticals-issues-voluntary-nationwide-recall-docetaxel-injection-usp-due-potential

#drugs #recall #us

Recent Interesting Reports

Baxter International Inc. announced today it has issued an Urgent Medical Device Recall for Life2000 ventilators with an attached battery charger dongle. The recall is due to reports that the devices are not properly charging when there is damage to the battery charger dongle. The impacted ventilators… See more

#recall #medicaldevices #us

American Health Packaging on behalf of BluePoint Laboratories is voluntarily recalling 21 batches of Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K, to the consumer level. The product is being recalled because of failed dissolution. The Potassium Chloride Extended-Release Capsules being recalled were distributed nationwide… See more

#recall #drugs #us